The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

Alphabet created Isomorphic Labs in 2021, spinning it out from DeepMind, the AI startup it acquired in 2014. DeepMind’s ...